Published in PLoS One on May 30, 2017
Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature (1998) 7.81
Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res (2010) 2.43
Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate (2004) 2.19
Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev (2001) 2.03
BPH: epidemiology and comorbidities. Am J Manag Care (2006) 2.01
Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res (2005) 1.77
Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest (2003) 1.60
Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate (2003) 1.59
Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest (1992) 1.57
Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 1.45
Inflammation and benign prostatic hyperplasia. Urol Clin North Am (2008) 1.44
Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl (2009) 1.43
Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. Cancer Res (2005) 1.41
hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Res (2006) 1.33
Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol (2009) 1.32
BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int (2008) 1.28
Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol (2001) 1.28
Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res (2005) 1.24
Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci U S A (2011) 1.21
The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation (2011) 1.16
Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res (2011) 1.15
Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem (2008) 1.14
In vitro stage-specific chondrogenesis of mesenchymal stem cells committed to chondrocytes. Arthritis Rheum (2009) 1.13
Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol (2013) 1.10
Telomerase accelerates osteogenesis of bone marrow stromal stem cells by upregulation of CBFA1, osterix, and osteocalcin. J Bone Miner Res (2003) 1.07
Hylan G-F 20 maintains cartilage integrity and decreases osteophyte formation in osteoarthritis through both anabolic and anti-catabolic mechanisms. Osteoarthritis Cartilage (2012) 1.07
Biochemical effects of two different hyaluronic acid products in a co-culture model of osteoarthritis. Osteoarthritis Cartilage (2006) 1.03
Immortalization without neoplastic transformation of human mesenchymal stem cells by transduction with HPV16 E6/E7 genes. Int J Cancer (2004) 1.02
Regenerative potentials of platelet-rich plasma enhanced by collagen in retrieving pro-inflammatory cytokine-inhibited chondrogenesis. Biomaterials (2011) 1.01
Benign prostatic hyperplasia: from bench to clinic. Korean J Urol (2012) 0.96
Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression. Eur Cytokine Netw (2000) 0.90
Aetiology and pathogenesis of benign prostatic hyperplasia. Curr Opin Urol (2003) 0.88
Establishment of a promising human nucleus pulposus cell line for intervertebral disc tissue engineering. Tissue Eng Part C Methods (2013) 0.88
Chronic inflammation in benign prostatic hyperplasia: implications for therapy. Med Hypotheses (2007) 0.87
Immortalization of a human prostate stromal cell line using a recombinant retroviral approach. J Urol (2000) 0.87
Recent role of inflammation in prostate diseases: chemoprevention development opportunity. Acta Med Indones (2011) 0.84
Ambivalent properties of hyaluronate and hylan during post-traumatic OA in the rat knee. Biomed Mater Eng (2012) 0.83
High molecular weight hyaluronan reduces lipopolysaccharide mediated microglial activation. J Neurochem (2012) 0.82
Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples. Int J Oncol (2013) 0.79
The effects of high molecular weight hyaluronic acid (Hylan G-F 20) on experimentally induced temporomandibular joint osteoartrosis: part II. Int J Oral Maxillofac Surg (2011) 0.77
Acute inflammation with induction of anaphylatoxin C5a and terminal complement complex C5b-9 associated with multiple intra-articular injections of hylan G-F 20: a case report. Osteoarthritis Cartilage (2012) 0.76
Tissue engineered cartilage using human articular chondrocytes immortalized by HPV-16 E6 and E7 genes. J Biomed Mater Res A (2006) 0.76